Danish pharma giant Novo Nordisk on Wednesday described better-than-anticipated earnings for 2023, propelled by a tsunami of need for its blockbuster weight loss and diabetes drugs as new treatments emerge and contend for any slice of your growing industry.Professional medical weight loss systems are powerful mainly because they incorporate dietary

Article Under Review